Ovid Therapeutics (OVID) Competitors

Immunic (NASDAQ:IMUX) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking, media sentiment and valuation.

Does the MarketBeat Community believe in IMUX or OVID?

Ovid Therapeutics received 254 more outperform votes than Immunic when rated by MarketBeat users. Likewise, 70.74% of users gave Ovid Therapeutics an outperform vote while only 64.71% of users gave Immunic an outperform vote.

Company	Underperform	Outperform
Immunic	Outperform Votes 99 64.71%	Underperform Votes 54 35.29%
Ovid Therapeutics	Outperform Votes 353 70.74%	Underperform Votes 146 29.26%

Is IMUX or OVID more profitable?

Immunic has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
Ovid Therapeutics	-5,142.56%	-39.24%	-26.19%

Do analysts prefer IMUX or OVID?

Immunic currently has a consensus target price of $12.25, suggesting a potential upside of 1,055.66%. Ovid Therapeutics has a consensus target price of $4.04, suggesting a potential upside of 281.13%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunic is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33
Ovid Therapeutics	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Do institutionals and insiders hold more shares of IMUX or OVID?

51.8% of Immunic shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by company insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more volatility and risk, IMUX or OVID?

Immunic has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Which has better valuation & earnings, IMUX or OVID?

Ovid Therapeutics has higher revenue and earnings than Immunic. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61M	-$1.23	-0.86
Ovid Therapeutics	$390K	193.00	-$52.34M	-$0.47	-2.26

Does the media prefer IMUX or OVID?

In the previous week, Ovid Therapeutics had 9 more articles in the media than Immunic. MarketBeat recorded 20 mentions for Ovid Therapeutics and 11 mentions for Immunic. Immunic's average media sentiment score of 0.89 beat Ovid Therapeutics' score of 0.26 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ovid Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ovid Therapeutics beats Immunic on 10 of the 17 factors compared between the two stocks.